Psychotropic drugs—neurotoxicity

References

• Skoutakis V. Rational management of tricyclic antidepressant poisonings. Clin. Tox. Consult. 1978; 1: 1
   Google Scholar
• Cairncross K. D., Gershon S., Gust I. D. Some aspects of the mode of action of imipramine. J. Neuropsychiatry 1962–1963; 4: 224
   Google Scholar
• Thompson E. A. Amitriptyline overdose. Drug Intell. Clin. Pharm. 1973; 7: 451
   Google Scholar
• Merrill D. C., Markland C. Vesical dysfunction induced by the major tranquilizers. J. Urol. 1972; 107: 769
   PubMed Web of Science ®Google Scholar
• Freeman J. W., Loughead M. G. Beta blockade in the treatment of tricyclic antidepressant overdosage. Med. J. Aust. 1973; 1: 1233
   PubMed Web of Science ®Google Scholar
• Innes I. R., Nickerson M. “Norepinephrine, epinephrine and the sympathomimetic amines,”. Pharmacological Basis of Therapeutics, L. S. Goodman, A. Gilman. Macmillan, New York 1975; 514
   Google Scholar
• Van Der Kolk B. A., Shader R. I., Greenblatt D. J. “Autonomic effects of psychotropic drugs,”. Psychopharmacology: A Generation of Progress, M. A. Lipton, A. Dimascio, F. Killam. Raven, New York 1978; 1009
   Google Scholar
• Byck R. “Drugs and the treatment of psychiatric disorders,”. Pharmacological Basis of Therapeutics, L. S. Goodman, A. Gilman. Macmillan, New York 1975; 152
   Google Scholar
• Williams R. B., Sherter C. Cardiac complications of tricyclic antidepressant therapy. Ann. Intern. Med. 1971; 74: 395
   PubMed Web of Science ®Google Scholar
• Domino E. F. “Psychosedative drugs I: Substituted phenothiazines, reserpine and derivatives,”. Drill's Pharmacology in Medicine, 3rd ed., J. R. Dipalma. McGraw-Hill, New York 1965; 356
   Google Scholar
• Rosatti D. Hypotensive side effects of phenothiazine and their management. Dis. Nerv. Syst. 1964; 25: 366
   PubMedGoogle Scholar
• Ropert R. Essias d'utilisation de l'ajmaline dans le traitement des troubles fonetionnels cardio-vasculaires observés aucours. Sem. Hop. 1973; 17: 1683
   Google Scholar
• Giarman N. J. “Antidepressant drugs,”. Drill's Pharmacology in Medicine, 3rd ed., J. R. Dipalma. McGraw-Hill, New York 1965; 365
   Google Scholar
• Schildkraut J. J. Neuropsychopharmacology and the Affective Disorders. Little Brown, Boston 1969
   Google Scholar
• Friend D. “Adverse cardiovascular and hematologic effects of psychotropic agents,”. Clinical Handbook of Psychopharmacology, A. Dimascio, R. I. Shader. Science House, New York 1970; 195
   Google Scholar
• Coull D. C., Crooks J., Dingwall-Fordyce I., Scott A. M., Weir R. D. Amitriptyline and cardiac disease. Lancet 1970; 2: 590
   PubMed Web of Science ®Google Scholar
• Williams R. B., Sherter C. Cardiac complications of tricyclic antidepressant therapy. Ann. Intern. Med. 1971; 74: 395
   PubMed Web of Science ®Google Scholar
• Alexander C. S., Nino A. Cardiovascular complications in young patients taking psychotropic drugs. Am. Heart J. 1969; 78: 757
   PubMed Web of Science ®Google Scholar
• Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963; 2: 849
   PubMed Web of Science ®Google Scholar
• Janecek J., Schiele B. C. Pargyline and tranylcypromine in the treatment of hospitalized depressed patients. J. New Drugs 1963; 3: 309
   PubMedGoogle Scholar
• Bronsky I. Carphenazine therapy of acutely psychotic patients in the psychiatric ward of a general hospital. Am. J. Psychiatry 1965; 121: 1203
   PubMed Web of Science ®Google Scholar
• Van Praag H. M. Psychotropic Drugs A Guide for the Practitioner. Brunner/Mazel, New York 1978
   Google Scholar
• Ebert M. E., Shader R. I. “Cardiovascular effects,”. Psychotropic Drug Side Effects Clinical and Theoretical Perspectives, R. I. Shader, A. Dimascio. Williams and Wilkins Co., Baltimore 1970; 149
   Google Scholar
• Cook W. A. Butyrylperazine and the elderly schizophrenic patient-A clinical appraisal. Med. J. Aust. 1966; 1: 935
   Google Scholar
• Kris E. B. Five year community follow-up of patients discharged from a mental hospital. Curr. Ther. Res. 1963; 5: 451
   PubMed Web of Science ®Google Scholar
• Wintrob R. M. Use of a long-acting phenothiazine in acute manic states. Dis. Nerv. Syst. 1967; 28: 323
   PubMedGoogle Scholar
• Honigfeld H., Newhall P. N. Hemodynamic effects of imipramine acetophenazine and trifluoperazine in geriatric psychiatry. Dis. Nerv. Syst. 1965; 26: 427
   PubMedGoogle Scholar
• Tamminga C. A., Smith R. C., Pandey G., Frohman L., Davis J. M. A neuroendocrine study of supersensitivity in tardive dyskinesia. Arch. Gen. Psychiatry 1977; 34: 1199
   PubMed Web of Science ®Google Scholar
• Goldstein B. J., Slater V., Miller J. Comparison of mesoridazine on chlordiazepoxide in psychiatric patients. Curr. Ther. Res. 1969; 11: 657
   PubMed Web of Science ®Google Scholar
• Stirman J. A. A comparison of methotrimeprazine and meperidine as analgesic agents. Anesth. Analg. 1967; 46: 176
   PubMed Web of Science ®Google Scholar
• Dundee J. W., Nicholl R. M., Clarke R. M., Moore R. S. J., Love W. L. Studies of drugs given before anesthesia. VII. Pethidine-phenothiazine combinations. Br. J. Anaesth. 1965; 37: 601
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health, Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch. Gen. Psychiatry 1964; 10: 246
   PubMed Web of Science ®Google Scholar
• Smith J. A., Baron A. R. Use of prothixene in the disturbed geriatric patient. Am. J. Psychiatry 1965; 122: 213
   PubMed Web of Science ®Google Scholar
• Wallerstein E., Dykyj R., Nodine J. H. Fluphenazine and amitriptyline in the anxious depressed patient. Am. J. Psychiatry 1967; 124: 397
   PubMed Web of Science ®Google Scholar
• Denzel H. A. Fluphenazine enanthate in the treatment of psychotic patients. Int. J. Neuropsychiatry 1966; 2: 258
   PubMedGoogle Scholar
• Noble J., Mathew H. Acute poisoning by tricyclic antidepressants: Clinical features and management of 100 patients. Clin. Toxicol. 1969; 2: 403
   Web of Science ®Google Scholar
• Vohra J. K. Cardiovascular abnormalities following tricyclic antidepressant drug overdosage. Drugs 1975; 7: 323
   Web of Science ®Google Scholar
• Iverson L. L. Inhibition of noradrenaline uptake by drugs. J. Pharm. Pharmacol. 1965; 17: 62
   PubMed Web of Science ®Google Scholar
• Brown T. C. K. Treatment of tricyclic overdosage arrhythmias. Pediatrics 1974; 54: 382
   Google Scholar
• Jefferson J. W. A review of cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom. Med. 1975; 37: 160
   PubMed Web of Science ®Google Scholar
• Serafimouski N., Thorball N., Asmussen I., Lunding M. Tricyclic antidepressive poisoning with special reference to cardiac complications. Acta Anesth. Scand. 1975; 19: 55
   PubMedGoogle Scholar
• Sigg E. B., Osborne M., Karol B. Cardiovascular effects of imipramine. J. Pharmacol. Exp. Ther. 1963; 141: 237
   PubMed Web of Science ®Google Scholar
• Brown K. G. E., McMicken H. U. S., Briggs D. S. Tachyarrhythmia in severe imipramine overdose controlled by practolol. Arch. Dis. Child. 1972; 47: 104
   PubMed Web of Science ®Google Scholar
• Thorstrand C. Clinical features in poisoning by tricyclic anti-depressants with special reference to the ECG. Acta Med. Scand. 1976; 199: 337
   PubMed Web of Science ®Google Scholar
• Spiker D. G., Weiss A. M., Chang J. S., Ruivitch J. F. F., Biggs J. T. Tricyclic antidepressant overdose: Clinical presentation and plasma levels. Clin. Pharmacol. Ther. 1975; 18: 539
   PubMed Web of Science ®Google Scholar
• Kantor S. J., Bigger J. T., Glassman A. H., Macken D. L., Perel J. M. Imipramine-induced heart block: A longitudinal case study. J. Am. Med. Assoc. 1975; 231: 1364
   PubMed Web of Science ®Google Scholar
• Shader R. I. Cardiac effects of imipramine HCl in the elderly. Psychopharm. Bull. 1975; 11: 15
   PubMedGoogle Scholar
• Hayes T. A., Pamtch M. L., Barker E. Imipramine dosage in children: A comment on “imipramine” and EKG abnormalities in hyperactive children. Am. J. Psychiatry 1975; 132: 546
   PubMed Web of Science ®Google Scholar
• Winsberg B. G., Goldstein S., Yepes L. E., Perel J. M. Imipramine and electrocardiographic abnormalities in hyperactive children. Am. J. Psychiatry 1975; 132: 542
   PubMed Web of Science ®Google Scholar
• Martin G. I., Zaug P. J. Electrocardiographic monitoring of enuretic children receiving therapeutic doses of imipramine. Am. J. Psychiatry 1975; 132: 540
   PubMed Web of Science ®Google Scholar
• Saraf K. R., Klein D. F., Gittelman-Klein R., Groff S. Imipramine side effects in children. Psychopharmacologia 1974; 37: 265
   PubMed Web of Science ®Google Scholar
• Rohner T. J. Imipramine toxicity. J. Urol. 1975; 114: 402
   PubMed Web of Science ®Google Scholar
• Sack R. L. “Side effects of adverse reactions to psychotropic medications,”. Psychopharmacology From Theory to Practice, J. C. Barchas, P. A. Berger, R. D. Ciaranello, G. R. Elliott. Oxford University Press, New York 1976; 276
   Google Scholar
• Burkitt E. A., Sutcliffe C. K. Paralytic ileus after amitriptyline (Tryptizol). Br. Med. J. 1961; 2: 1648
   Web of Science ®Google Scholar
• Gander D. R., Devlin H. B. Ileus after amitriptyline. Br. Med. J. 1963; 1: 1160
   PubMedGoogle Scholar
• Lyle W. H. Adynamic ileus and nortriptyline. Br. Med. J. 1966; 1: 980
   PubMed Web of Science ®Google Scholar
• Shader R. I., Harmatz J. S. “Gastrointestinal effects,”. Psychotropic Drug Side Effects, R. I. Shader, A. Dimascio. Williams and Wilkins, Baltimore 1970; 198
   Google Scholar
• Ritama V., Vapaatalo H. I., Neuronen P. J., Idänpään J. E., Paasonen M. K. Phenothiazines and intestinal dilation. Lancet 1969; 1: 470
   PubMed Web of Science ®Google Scholar
• How J., Strachan R. W. Acute dilation of stomach as late complication of drug overdose. Br. Med. J. 1976; 1: 563
   PubMed Web of Science ®Google Scholar
• Ayd F. J. Amitriptyline: Reappraisal after six years experience. Dis. Nerv. Syst. 1965; 26: 719
   PubMedGoogle Scholar
• Greer M. Drug therapy in Parkinson's disease. South. Med. J. 1978; 71: 448
   PubMed Web of Science ®Google Scholar
• Petrie G., Pórszász J., Pórszász-Gibiszer K. The action of sympatholytic drugs in experimental intestinal paralysis. Acta Chir. Acad. Sci. Hung. 1971; 12: 393
   Google Scholar
• Petri G., Szenohradszky J., Pórszász-Gibiszer K. Sympatholytic treatment of paralytic ileus. Surgery 1971; 70: 359
   PubMed Web of Science ®Google Scholar
• Hussan A. E., Bragg D. G. The effect of chlorpromazine on the swallowing functions in chronic schizophrenic patients. Am. J. Psychiatry 1969; 126: 570
   PubMed Web of Science ®Google Scholar
• Tyber M. A. The relationship between hiatus hernia and anti-depressants: A report of five cases. Am. J. Psychiatry 1975; 132: 652
   PubMed Web of Science ®Google Scholar
• Hsu J. J., Yap A. T. Autonomic reactions in relation to psychotropic drugs. Dis. Nerv. Syst. 1976; 28: 304
   Google Scholar
• Ellis S. “The Autonomic Nervous System-General Considerations,”. Drill's Pharmacology in Medicine, J. R. Dipalma. McGraw-Hill, New York 1965; 411
   Google Scholar
• Grant W. M. Ocular complication of drugs. J. Am. Med. Assoc. 1969; 207: 2089
   Web of Science ®Google Scholar
• Lowe R. F. Amitriptyline glaucoma. Med. J. Aust. 1966; 2: 509
   PubMedGoogle Scholar
• Lazenby G. W., Reed J. W., Grant K. V. M. Anticholinergic medication in open-angle glaucoma. Arch. Ophthalmol. 1970; 84: 719
   PubMed Web of Science ®Google Scholar
• Nouri A., Cuedet J. F. Atteintes oculaires au cours des tratiments aux thymoleptiques. Schweiz. Med. Wochenschr. 1971; 101: 1178
   PubMedGoogle Scholar
• Roberts W. The use of psychotropic drugs in glaucoma. In prolonged pharmacotherapy and the eye. Dis. Nerv. Syst. 1968; 29: 40
   PubMedGoogle Scholar
• Hordern A., Holt N. F., Burt C. G., Gordon W. F. Amitriptyline depressive states. Br. J. Psychiatry 1963; 109: 815
   PubMed Web of Science ®Google Scholar
• Hordern A., Burt C. G., Gordon W. F., Holt N. F. Amitriptyline in depressive states: Six months treatment results. Br. J. Psychiatry 1964; 110: 641
   PubMed Web of Science ®Google Scholar
• Bock R. Ophthalmologic findings in patients on long term chlorpromazine therapy. Am. J. Ophthalmol. 1963; 56: 808
   PubMed Web of Science ®Google Scholar
• Goldovskaya I. L. Ob oftal'mologicheskom obsledovanii bolnykh; poluchaiushchileh psikhotropnye preparaty. Zh. Nevropatol. Psikhiatr. im. K. K. Korsakova 1970; 70: 759
   PubMedGoogle Scholar
• Belfer M. L., Shader R. I. “Autonomic effects,”. Psychotropic Drugs Side Effects, R. I. Shader, A. Dimascio. Williams and Wilkins, Baltimore 1970; 116
   Google Scholar
• Martin M. E. Comparative trial of imipramine and phenelzine in the treatment of depression. Br. J. Psychiatry 1963; 109: 279
   Web of Science ®Google Scholar
• Plavec J., Steininger E. Protriptyline in klinischer und ambulanter Anwendung bei verscheidenen Formen der Depression. Wien. Med. Wochenschr. 1968; 118: 983
   PubMedGoogle Scholar
• Krumholz W. V., Sheppard C., Merlis S. Clinical evaluation of butaperazine (AHR712). Curr. Ther. Res. 1967; 9: 220
   PubMed Web of Science ®Google Scholar
• Beerman H. M. A controlled study of diazepam in psychiatric outpatients. Am. J. Psychiatry 1964; 120: 870
   PubMed Web of Science ®Google Scholar
• Goldstein G. J. Haloperidol in controlling the symptoms of acute psychoses, Part I. A preliminary investigation. Curr. Ther. Res. 1966; 8: 232
   PubMed Web of Science ®Google Scholar
• Barringer T. J. Clinical trial of desipramine in the treatment of depression. Am. J. Psychiatry 1965; 121: 117
   Google Scholar
• Pratt J. P., Bishop M. P., Gallant D. M. Trifluperidol and haloperidol in the treatment of acute schizophrenia. Am. J. Psychiatry 1964; 121: 592
   PubMed Web of Science ®Google Scholar
• Koelle G. B. “Neurohumoral transmission and the autonomic nervous system,”. Pharmacological Basis of Therapeutics, L. S. Goodman, A. Gilman. Macmillan, New York 1975; 404
   Google Scholar
• Jonas S. Miosis following administration of chlorpromazine and related agents. Am. J. Psychiatry 1959; 115: 817
   PubMed Web of Science ®Google Scholar
• Merrill D. C., Markland C. Vesical dysfunction induced by the major tranquilizers. J. Urol. 1972; 107: 769
   PubMed Web of Science ®Google Scholar
• Shearer W. T., Scheiner R. L., Marshall R. E. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J. Pediatr. 1972; 81: 570
   PubMed Web of Science ®Google Scholar
• Everett H. C. The use of bethanechol chloride with tricyclic antidepressants. Am. J. Psychiatry 1975; 132: 1202
   PubMed Web of Science ®Google Scholar
• Maclean R. E. G. Imipramine hydrochloride (Tofranil) and enuresis. Am. J. Psychiatry 1960; 117: 551
   PubMed Web of Science ®Google Scholar
• Mariuz M. J., Walters C. J. Enuresis in non-psychotic boys treated with imipramine. Am. J. Psychiatry 1963; 120: 597
   PubMed Web of Science ®Google Scholar
• Appel P., Eckel K., Harrer G. Veränderungen des Blasen und Blasensphinktertonus durch Thymoleptic. Int. Pharmacopsychiatry 1971; 6: 15
   PubMedGoogle Scholar
• Werry J. S., Dowrick P. W., Lampen E. L., Vamos M. J. Imipramine in enuresis psychological and physiological effects. J. Child Psychiatry 1975; 16: 289
   Google Scholar
• Hagglund T. B., Parkkulaninen K. V. Enuretic children treated with imipramine (Tofranil): A cystometric study. Ann. Pediatr. Fenn. 1965; 2: 53
   Google Scholar
• Shader R. I. “Male sexual function,”. Psychotropic Drug Side Effects, R. I. Shader, A. Dimascio. Williams and Wilkins, Baltimore 1970; 63
   Google Scholar
• Palmai G., Blackwell B., Maxwell A. E., Morgenstern F. Patterns of salivary flow in depressive illness and during treatment. Br. J. Psychiatry 1967; 113: 1297
   Web of Science ®Google Scholar
• Angst J., Theobald W. Tofranil (Imipramine). Stämpfli, Bern 1970
   Google Scholar
• Wolpert A., Sheppard C., Merlis S. An early clinical evaluation of clopenthixol in treatment of resistant female schizophrenic patients. Am. J. Psychiatry 1967; 124: 702
   PubMed Web of Science ®Google Scholar
• Holden J. M. C., Itil T. M., Cannon P. J. Clinical effects of intramuscular thiothixene and trifluperazine in chronic schizophrenia: A comparative study. Curr. Ther. Res. 1971; 13: 298
   PubMed Web of Science ®Google Scholar
• Ford C. V., Gottlieb F. An objective evaluation of haloperidol in Gilles de la Tourette syndrome. Dis. Nerv. Syst. 1969; 30: 328
   PubMedGoogle Scholar
• Aldous J. A. Induced xerostomia and its relation to dental caries. J. Dent. Child. 1964; 31: 160
   Google Scholar
• Kane F. J. Oral moniliasis following the use of Thorazine. Am. J. Psychiatry 1963; 120: 187
   PubMed Web of Science ®Google Scholar
• Worthington J. J. Severe toxin reaction to combined amitriptyline and thioridazine. Am. J. Psychiatry 1965; 121: 812
   PubMed Web of Science ®Google Scholar
• Green M. Inhibition of ejaculation as a side effect of Mellaril. Am. J. Psychiatry 1961; 118: 172
   PubMed Web of Science ®Google Scholar
• Shader R. I. “Ejaculation disorders,”. Psychotropic Drug Side Effects, R. I. Shader, A. Dimascio. Williams and Wilkins, Baltimore 1970; 72
   Google Scholar
• Shader R. I. Sexual dysfunction associated with thioridazine hydrochloride. J. Am. Med. Assoc. 1964; 188: 1007
   PubMed Web of Science ®Google Scholar
• Freyhan F. A. Loss of ejaculation during Mellaril treatment. Am. J. Psychiatry 1961; 118: 171
   PubMed Web of Science ®Google Scholar
• Kotin J., Wilbert D. E., Vergurn D., Soldinger S. M. Thioridazine and sexual dysfunction. Am. J. Psychiatry 1976; 133: 82
   PubMed Web of Science ®Google Scholar
• Vinarova E., Uhlir O., Stika L., Vinar O. Side effects of lithium administration. Act. Nerv. Super. 1972; 14: 105
   PubMedGoogle Scholar
• Heller J. Another case of inhibition of ejaculation as side effect of Mellaril. Am. J. Psychiatry 1961; 118: 173
   PubMed Web of Science ®Google Scholar
• Blair J. H., Simpson G. M. Effect of antipsychotic drugs on reproductive function. Dis. Nerv. Syst. 1966; 27: 645
   PubMedGoogle Scholar
• Dimascio A. “Behavioral toxicity,”. Clinical Handbook of Psychopharmacology, A. Dimascio, R. I. Shader. Science House, New York 1970; 185
   Google Scholar
• Crane G. E. Tardive dyskinesia in patients treated with major neuroleptics: A review of the literature. Am. J. Psychiatry 1968; 124: 40
   PubMed Web of Science ®Google Scholar
• Crane G. E., Ruiz P., Kernohan W. J., Wilson W., Royalty N. Effects of drug withdrawal on tardive dyskinesai. Act. Nerv. Super. 1969; 11: 30
   PubMedGoogle Scholar
• Crane G. E. High doses of trifluperazine and tardive dyskinesia. Arch. Neurol. 1970; 22: 176
   PubMed Web of Science ®Google Scholar
• Crane G. E. Prevention and management of tardive dyskinesia. Am. J. Psychiatry 1972; 129: 466
   PubMed Web of Science ®Google Scholar
• Crane G. E. Dyskinesia and neuroleptics. Arch. Gen. Psychiatry 1968; 19: 700
   PubMed Web of Science ®Google Scholar
• Crane G. E., Smeets R. A. Tardive dyskinesia and drug therapy in geriatric patients. Arch. Gen. Psychiatry 1974; 30: 341
   PubMed Web of Science ®Google Scholar
• Crane G. E. “Risks of long-term therapy with neuroleptic drugs,”. Pharmacodynamics and Pharmacokinetics, G. Sedvall, B. Uvnas. Pergamon, New York 1976; 411
   Google Scholar
• Crane G. E. The prevention of tardive dyskinesia. Am. J. Psychiatry 1977; 134: 756
   PubMed Web of Science ®Google Scholar
• Crane G. E. “Prevention of tardive dyskinesia,”. Current Psychiatric Therapy, J. H. Masserman. Grune and Stratton. 1977; 227
   Google Scholar
• Crane G. E. “Tardive dyskinesia and related neurologic disorders,”. Handbook of Psychopharmacology, L. Iverson, S. D. Iverson, S. Snyder. Plenum, New York 1978; 185
   Google Scholar
• Baldessarini R. J., Tarsy D. “Tardive dyskinesia,”. Psychopharmacology: A Generation of Progress, M. A. Lipton, A. Dimascio, K. F. Killam. Raven, New York 1978; 993
   Google Scholar
• Paulson G. W. Tardive dyskinesia. Annu. Rev. Med. 1975; 26: 75
   PubMed Web of Science ®Google Scholar
• Schönecker M. Ein eigentumliches syndrome im bereich bei megaphen applikation. Nervenarzt 1957; 28: 35
   PubMedGoogle Scholar
• Faurbye A., Rasch P. J., Peterson P. B., Brandborg C., Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr. Scand. 1964; 40: 10
   PubMed Web of Science ®Google Scholar
• Hunter R., Earl C. J., Thornicroft S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc. R. Soc. Med. 1964; 57: 758
   PubMedGoogle Scholar
• Degkwitz R., Wenzel W., Binsack K. R., Herkert F., Luxenburger O. Zum probleme der terminalen extrapyramidalen hyperkinesen an hand von 1600 langfristig mit neuroleptica behandelten. Arzneimittelforschung 1966; 16: 276
   PubMed Web of Science ®Google Scholar
• Degkwitz R., Binsack K. F., Herkert H., Luxenburger O., Wenzel W. Zum probleme der persistietend hyperkinesen nach langfristiger anwendung von neuroleptika. Nervenarzt 1967; 38: 170
   PubMedGoogle Scholar
• Garver D. L., Davis J. M., Dekirmenjian H., Ericksen S., Gosenfeld L., Haraszti J. Dystonic reactions following neuroleptics time course and proposed mechanisms. Psychopharmacology 1976; 47: 199
   PubMed Web of Science ®Google Scholar
• Rifkin A., Quitkin F., Kane J., Klein D. F. Fluphenazine decanoate, oral fluphenazine and placebo in the treatment of remitted schizophrenics. II. Rating scale data. Psychopharm. Bull. 1977; 13: 49
   PubMedGoogle Scholar
• Hollister L. E. “Interactions of psychotherapeutic drugs with other drugs and disease states,”. Psychopharmacology: A Generation of Progress, M. A. Lipton, A. Dimascio, K. F. Killan. Raven, New York 1978; 987
   Google Scholar
• Vacaflor L., Lehmann H. E., Ban T. A. Side effects of lithium carbonate treatment. J. Clin. Pharmacol. J. New Drugs 1970; 10: 387
   PubMedGoogle Scholar
• Kellett J. M., Metcalfe M., Bailey J., Coppen A. J. Beta blockade in lithium tremor. J. Neurol., Neurosurg. Psychiatry 1975; 38: 719
   PubMed Web of Science ®Google Scholar
• Lapierre Y. D. Control of lithium tremor with propranolol. Can. Med. Assoc. J. 1976; 114: 619
   PubMed Web of Science ®Google Scholar
• Floru L. Die anwendung beta-blockierender substanzen in der psychiatrie und neurologic. Fortschr. Neurol. Psychiatr. 1977; 45: 112
   Google Scholar
• Carlsson A., Lindquist M., Magnusson T. 3,4-Dihydroxy-phenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature (London) 1957; 180: 1200
   PubMed Web of Science ®Google Scholar
• Hornykewicz D. Mechanism of action of L-DOPA in Parkinson's disease. Life Sci. 1974; 15: 1249
   PubMed Web of Science ®Google Scholar
• Arvidson J., Roos B. E., Steg G. Reciprocal effects on alpha and gamma motoneurons of drugs influencing monoaminergic and cholinergic transmission. Acta Physiol. Scand. 1966; 67: 298
   Google Scholar
• Daprada M., Pletscher A. On the mechanism of chlorpromazine-induced changes of cerebral homovanillic acid. J. Pharm. Pharmacol. 1966; 18: 628
   PubMed Web of Science ®Google Scholar
• Keller H. H., Bartholini G., Pletscher A. Increase of 3-methoxy-4-hydroxy-phenyl ethyleneglycol in rat brain by neuroleptic drugs. Eur. J. Pharmacol. 1973; 23: 183
   PubMed Web of Science ®Google Scholar
• Bunney B. S., Walters J. R., Roth R. H., Aghajanian G. K. Dopaminergic neurons: Effects of antipsychotics and amphetamines on single cell activity. J. Pharm. Pharmacol. 1973; 185: 560
   Google Scholar
• Nyback H., Sedvall G. Further studies on the accumulation and disappearance of catecholamine formed from tyrosine-14C in mouse brain. Effect of some phenothiazine analogues. Eur. J. Pharmacol. 1970; 10: 193
   PubMed Web of Science ®Google Scholar
• Bartholini G., Pletscher A. Enhancement of tyrosine hydroxylation within the brain by chlorpromazine. Experientia 1969; 25: 919
   PubMedGoogle Scholar
• Bartholini G., Pletscher A. “Drugs affecting monoamines in the basal ganglia,”. Advances in Biochemical Psychopharmacology, E. Costa, L. L. Iverson, R. Paoletti. Raven, New York 1972; 135
   Google Scholar
• Bartholini G., Haefely W., Jalfre M., Keller H. H., Pletscher A. Effects of clozapine on cerebral neuronal systems. Br. J. Pharmacol. 1972; 46: 736
   PubMed Web of Science ®Google Scholar
• Anden N. E., Stock G. Effects of clozapine on the turnover of dopamine in the corpus striatum and the limbic system. J. Pharm. Pharmacol. 1973; 25: 346
   PubMed Web of Science ®Google Scholar
• Branchey M. H., Charles J., Simpson G. M. Extrapyramidal side effects in lithium maintenance therapy. Am. J. Psychiatry 1976; 133: 444
   PubMed Web of Science ®Google Scholar
• Shopsin B., Gershon S. Cogwheel rigidity related to lithium maintenance. Am. J. Psychiatry 1975; 132: 536
   PubMed Web of Science ®Google Scholar
• Simpson G. M., Amuso D., Blair J. H. Phenothiazine extra-pyramidal system disturbances. Arch. Gen. Psychiatry 1964; 10: 199
   PubMed Web of Science ®Google Scholar
• Wartenberg R. The Examination of Reflexes. Year Book Medical Publishers, Chicago 1945
   Google Scholar
• Pearce J., Azis H., Gallagher J. C. Primitive reflex activity in primary and symptomatic parkinsonism. J. Neurol. Neurosurg. Psychiat. 1968; 31: 501
   PubMed Web of Science ®Google Scholar
• Klawans H. L., Goodwin J. A. Reversal of the glabellar reflex in parkinsonism by L-DOPA. J. Neurol., Neurosurg. Psychiatry 1969; 32: 423
   PubMed Web of Science ®Google Scholar
• Crane G. E. Clinical psychopharmacology in its 20th year. Science 1973; 181: 124
   PubMed Web of Science ®Google Scholar
• Hill R. M., Desmond M. M., Kay J. L. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J. Pediatr. 1966; 69: 589
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Dopamine and brain function. Pharmacol. Rev. 1966; 18: 925
   PubMed Web of Science ®Google Scholar
• Lloyd K. G., Hornykiewizc O. “Metabolism of levodopa in the human brain,”. Neurology, D. B. Calne. Raven, New York 1973; 173
   Google Scholar
• Hornykiewicz O. “Metabolism of brain dopamine in human parkinsonism: Neurochemical and clinical aspects,”. Biochemistry and Pharmacology of the Basal Ganglia, E. Costa, L. J. Cote, M. D. Yahr. Raven, New York 1966; 171
   Google Scholar
• Lloyd K. G., Hornykiewicz O. “Catecholamines in regulation of motor function,”. Catecholamines and Behavior, A. Friedhoff. Plenum, New York 1975; 41
   Google Scholar
• Dimascio A., Soltys J. J., Shader R. I. “Psychotropic drugs side effects in children,”. Psychotropic Drug Side Effects, R. I. Shader, A. Dimascio, W. S. Appleton, M. F. Belfer, M. H. Ebert, D. R. Giller, J. S. Greenblatt, J. P. Harmatz, H. Nahum, C. Pearlman, C. Salzman, J. J. Soltys. Williams and Wilkins, Baltimore 1970; 235
   Google Scholar
• McAndrew J. B., Case Q., Treffert D. A. Effects of prolonged phenothiazine intake in psychotic and other hospitalized children. J. Autism Child. Schizophr. 1972; 2: 75
   PubMedGoogle Scholar
• Engelhardt D. M., Polizos P., Waizer J. CNS consequences of psychotropic drug withdrawal in autistic children: A follow up report. Psychopharmacol. Bull. 1975; 11: 6
   PubMedGoogle Scholar
• Engelhardt D. M., Polizos P. “Adverse effects of pharmacotherapy in childhood psychosis,”. Psychopharmacology: A Generation of Progress, M. A. Lipton, A. Dimascio, K. F. Killam. Raven, New York 1978; 1463
   Google Scholar
• Degwitz R. “Extrapyramidal motor disorders following long-term treatment with neuroleptic drugs,”. Psychotropic Drugs and Dysfunction of the Basal Ganglia, G. E. Crane, R. Gardner, Jr. U.S. Public Health Service Publication, Washington, D.C. 1969; 22, (No. 1938)
   Google Scholar
• Moline R. A. Atypical tardive dyskinesia. Am. J. Psychiatry 1964; 121: 491
   PubMedGoogle Scholar
• Crane G. E. Rapid reversal of tardive dyskinesia. Am. J. Psychiatry 1973; 130: 1159
   PubMed Web of Science ®Google Scholar
• Crane G. E. Tardive dyskinesia: A review in neuropsychopharmacology, Proceedings of the 6th Congress of the Collegium Internationale Neuropsychopharmacologium. Excerpta Med. Int. Congr. Ser. 1974; 359: 346
   Google Scholar
• Schmidt W. R., Jarcho L. W. Persistant dyskinesias following phenothiazine therapy. Arch. Neurol. 1966; 14: 369
   PubMed Web of Science ®Google Scholar
• Gardos G., Cole J. O., Labrie R. The assessment of tardive dyskinesia. Arch. Gen. Psychiatry 1977; 34: 1206
   PubMed Web of Science ®Google Scholar
• Fidler S. M., O'Rourke R. A., Bucksbaum H. W. Choreoathetosis as a manifestation of thyrotoxicosis. Neurology 1971; 21: 55
   PubMed Web of Science ®Google Scholar
• Brandon S., McClelland H. A., Protherob C. A study of facial dyskinesia in a mental hospital population. Br. J. Psychiatry 1971; 118: 171
   PubMed Web of Science ®Google Scholar
• Appenzeller O., Biehl J. P. Mouthing in the elderly. Neurology 1967; 17: 290
   Web of Science ®Google Scholar
• Hippius H., Logemann G. Zur wirkung von dioxyphenylalinin (L-DOPA) auf extrapyramidal-motorische hyperkinesen nach langfristiger neuroleptischer therapie. Arzneim.-Forsch. 1970; 20: 894
   PubMedGoogle Scholar
• Klawans H. L., McKendall R. R. Observations on the effect of L-DOPA on tardive lingual-facial-buccal dyskinesia. J. Neurol. Sci. 1971; 14: 189
   PubMed Web of Science ®Google Scholar
• Godwin-Austen R. B., Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br. Med. J. 1971; 4: 25
   PubMed Web of Science ®Google Scholar
• Roxburgh P. A. Treatment of persistent phenothiazine-induced oral dyskinesia. Br. J. Psychiatry 1970; 116: 277
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H., Chien C., Cole J. O. Treatment of tardive dyskinesia, Part 2. Arch. Gen. Psychiatry 1972; 27: 100
   PubMedGoogle Scholar
• Klawans H. L., Ilahi M. M., Shenker D. Theoretical implications of the use of L-DOPA in parkinsonism. Acta Neurol. Scand. 1970; 46: 409
   PubMed Web of Science ®Google Scholar
• Chase T. N. Drug-induced extrapyramidal disorders. Res. Publ. Assoc. Nerv. Ment. Dis. 1972; 50: 448
   PubMedGoogle Scholar
• Korczyn A. D. Pathophysiology of drug-induced dyskinesias. Neuropharmacology 1972; 11: 601
   PubMed Web of Science ®Google Scholar
• Klawans H. L. The Pharmacology of Extrapyramidal Movement Disorders. Karger, Basel 1973
   Google Scholar
• Ayd F. J. “Prevention of recurrence (maintenance therapy),”. Clinical Handbook of Psychopharmacology, A. Dimascio, R. I. Shader. Science House, New York 1970; 297
   Google Scholar
• Hershon H. I., Kennedy P. F., McGuire R. J. Persistence of extrapyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br. J. Psychiatry 1972; 120: 41
   PubMed Web of Science ®Google Scholar
• Bordelaise J. M., Albert J. M., Hillel J., Tetreault L. Medication antiparkinsonienne et bilan extrapyramidal, etude de trihexphendyl. Can. Psychiatr. Assoc. J. 1967; 12: 585
   Google Scholar
• Curran J. P. Management of tardive dyskinesia with thiopropazate. Am. J. Psychiatry 1973; 130: 925
   PubMed Web of Science ®Google Scholar
• Ayd F. A. A survey of drug-induced extrapyramidal reactions. J. Am. Med. Assoc. 1961; 175: 1054
   PubMed Web of Science ®Google Scholar
• Swett C. Drug-induced dystonia. Am. J. Psychiatry 1975; 132: 532
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H., Chien C. P., Cole J. O. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am. J. Psychiatry 1973; 130: 179
   PubMedGoogle Scholar
• Claveria L. E., Teychenne P. F., Calne D. B., Haskayne L., Petrie A., Pallis C. A., Lodge-Patch I. C. Tardive dyskinesia treated with pimozide. J. Neurol. Sci. 1975; 24: 393
   PubMed Web of Science ®Google Scholar
• Fog R., Pakkenberg H. Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes. Acta Neurol. Scand. 1970; 46: 249
   PubMed Web of Science ®Google Scholar
• Villeneuve A., Boszormenyi Z. Treatment of drug-induced dyskinesias. Lancet 1970; 1: 353
   PubMed Web of Science ®Google Scholar
• Crane G. E. Mediocre effects of reserpine on tardive dyskinesia. New Engl. J. Med. 1973; 288: 104
   PubMedGoogle Scholar
• Kazamatsuri H., Chien C. P., Cole J. O. Treatment of tardive dyskinesia III: Clinical efficacy of a dopamine competing agent, methyldopa. Arch. Gen. Psychiatry 1972; 21: 824
   Google Scholar
• Gerlach J., Thorsen K. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and dopaminergic treatment. Int. Pharm. 1976; 11: 1
   Google Scholar
• Simpson G. M. Letter to the editor, Tardive dyskinesia. Br. J. Psychiatry 1978; 122: 618
   Google Scholar
• Simpson G. M., Branchey M. H., Lee J. H., Voitashevsky A., Zoubok B. Lithium in tardive dyskinesia. Pharmakopsychiatr./Neuro-Psychopharmakol. 1976; 9: 76
   PubMedGoogle Scholar
• Reda F. A., Escobar J. I., Scanlan J. M. Lithium carbonate in the treatment of tardive dyskinesia. Am. J. Psychiatry 1975; 132: 560
   PubMed Web of Science ®Google Scholar
• Goldman D. Treatment of phenothiazine-induced dyskinesia. Psycho-pharmacology 1976; 47: 271
   PubMed Web of Science ®Google Scholar
• Casey D. E., Denney D. Deanol in the treatment of tardive dyskinesia. Am. J. Psychiatry 1975; 132: 864
   PubMed Web of Science ®Google Scholar
• Miller E. Deanol in the treatment of levodopa-induced dyskinesias. Neurology 1974; 24: 116
   PubMed Web of Science ®Google Scholar
• Growdon J. H., Hirsch M. J., Wurtman R. J. Oral choline administration to patients with tardive dyskinesia. N. Engl. J. Med. 1977; 297: 524
   PubMed Web of Science ®Google Scholar
• Davis K. L., Hollister L. E., Barchas J. C. Choline in tardive dyskinesia and Huntington's disease. Life Sci. 1976; 19: 1507
   PubMed Web of Science ®Google Scholar
• Cohen E. L., Wurtman R. J. Brain acetylcholine increase after systemic choline administration. Life Sci. 1975; 16: 1095
   PubMed Web of Science ®Google Scholar
• Growdon J. H., Cohen E. L., Wurtman R. J. Effects of oral choline administration of serum and CSF choline levels in patients with Huntington's disease. J. Neurochem. 1977; 28: 229
   PubMed Web of Science ®Google Scholar
• Wurtman R. J., Hirsch M. J., Growdon J. H. Lecithin consumption elevates serum free choline levels. Lancet 1977; 2: 68
   PubMed Web of Science ®Google Scholar
• Growdon J. H., Gelenberg A. J., Doller J., Hirsch M. J., Wurtman R. J. Lecithin can suppress tardive dyskinesia. N. Engl. J. Med. 1978; 298: 1029
   PubMed Web of Science ®Google Scholar
• Korsgaard S. Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia. Acta Psychiatr. Scand. 1976; 54: 17
   PubMed Web of Science ®Google Scholar
• Linnoila M., Viukario M., Hietala O. Effect of sodium valproate on tardive dyskinesia. Br. J. Psychiatry 1976; 129: 114
   PubMed Web of Science ®Google Scholar
• Cohen W. J., Cohen N. H. Lithium carbonate, haloperidol and irreversible brain damage. J. Am. Med. Assoc. 1974; 230: 1283
   PubMed Web of Science ®Google Scholar
• Crane G. E. Persistent dyskinesia. Br. J. Psychiatry 1973; 122: 395
   PubMed Web of Science ®Google Scholar
• Harenko A. Retrocollis as an irreversible late complication of neuroleptic medication. Acta Neurol. Scand. 1967; 43: 145
   PubMed Web of Science ®Google Scholar
• Pritchard M. Prognosis of schizophrenia before and after pharmacotherapy: Three year follow-up. Br. J. Psychiatry 1967; 113: 1353
   PubMed Web of Science ®Google Scholar
• Lloyd K. G. “Neurochemical compensation,”. Parkinson's Disease Concepts and Prospects, J. P. W. F. Lakke, J. Korf, H. Wesseling. Excerpta Medica, Amsterdam 1977; 61, Proceedings of a Symposium Held at the University of Groningen
   Google Scholar
• Rastogi S. K., Tewari J. P., Srivastava M. C. Recent concepts in the pharmacotherapy of parkinsonism. J. Indian Med. Assoc. 1977; 69: 59
   PubMedGoogle Scholar
• Shader R. I., Elkins R., Ciraulo D., Salzman C. On guidelines for maximum dosages. Am. J. Psychiatry 1978; 135: 499
   PubMed Web of Science ®Google Scholar
• Crane G. E. Dr. Crane replies to “On guidelines for maximum dosage,”. Am. J. Psychiatry 1978; 135: 400
   Google Scholar